TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31371345
Drug: INCB054828 (pan-FGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054828 (pan-FGFR inhibitor)
Study: 31371414
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) treatment, 5 g/m², during consolidation therapy.
Study: 31371644
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin treatment
Study: 31373712
Drug: Standardised mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standardised mesalazine therapy
Study: 31374300
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dupilumab weekly for up to 76 weeks
Study: 31374487
Drug: Lacosamide ≤8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide ≤8 mg/kg/day for Cohort 1 (aged 5-11 years); ≤12 mg/kg/day (≤600 mg/day) for age-based cohorts 2-5
Study: 31374487
Drug: Lacosamide treatment
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide treatment
Study: 31377161
Drug: Moderate hypofractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypofractionation (MH-RT; 26 fractions of 2.7 Gy to a total dose of 70.2 Gy)
Study: 31377161
Drug: Extreme hypofractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extreme hypofractionation (EH-RT; fractions of 6.5-7 Gy to a total dose of 32.5-35 Gy)
Study: 31377265
Drug: Triac (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triac (350 μg initial dose, escalating in 350 μg increments)
Study: 31377265
Drug: Triac (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triac (mean dose of 38.3 μg/kg, range 6.4-84.3 μg/kg)
Study: 31377694
Drug: Salvage stereotactic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage stereotactic body radiotherapy (SBRT) with doses of 5×6, 6×6, or 5×5 Gy
Study: 31378459
Drug: Tislelizumab 200
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200 mg every 3 weeks plus pamiparib 40 mg twice daily (recommended phase 2 dose)
Study: 31379605
Drug: Aquatic endurance
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic endurance training (2-week, twice daily)
Study: 31379605
Drug: Land-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based exercise training (2-week, twice daily)
Study: 31379673
Drug: Compassion-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-Focused Therapy (CFT)
Study: 31379734
Drug: Subcutaneous Pasireotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Pasireotide
Study: 31380382
Drug: Novel Microbial-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel Microbial-Based Immunotherapy
Study: 31382020
Drug: Omalizumab therapy
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab therapy (mean dosage 473 mg every 4 weeks, mean duration 2.49 years)
Study: 31382942
Drug: Warfarin educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin educational video delivered on an electronic tablet (iPad)
Study: 31383812
Drug: Irinotecan and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan and etoposide (oral etoposide at 50 mg/day on days 1-14 and intravenous irinotecan at 100 mg/m2)
Study: 31384312
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with docetaxel and cyclophosphamide (75/600 mg/m2) for four 3-weekly cycles
Study: 31384312
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with docetaxel and cyclophosphamide
Study: 31385109
Drug: Anti-endothelin B
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-endothelin B receptor antibody-drug conjugate DEDN6526A; specific dosage and duration not mentioned.
Study: 31385389
Drug: Standard course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard course of systemic corticosteroid and antibiotic treatment
Study: 31385389
Drug: Eosinophil count
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eosinophil count <0.144 × 10^9/L
Study: 31385617
Drug: Maribavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (400 mg twice daily for 8 days)
Study: 31386611
Drug: Response- and
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response- and biology-based therapy
Study: 31387885
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and cetuximab
Study: 31388454
Drug: ASP8232 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8232 40 mg monotherapy
Study: 31388454
Drug: ASP8232 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8232 40 mg and monthly intravitreal ranibizumab 0.3 mg combination therapy
Study: 31388454
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab 0.3 mg monotherapy
Study: 31388703
Drug: Intravenous metamizole
Normalized name: Metamizole
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metamizole (10 mg/kg)
Study: 31390274
Drug: Gemcitabine-eribulin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine-eribulin combination treatment
Study: 31391177
Drug: Monthly cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly cyclophosphamide (CYC) treatment
Study: 31391203
Drug: Four diabetes
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four diabetes medications added to metformin
Study: 31392048
Drug: Lanreotide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide monotherapy
Study: 31392200
Drug: Liver depot
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver depot gene therapy using an AAV vector for GAA production
Study: 31392200
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (GAA)
Study: 31394574
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III)
Study: 31395751
Drug: Binimetinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (45 mg twice daily) and Buparlisib (80 mg once daily)
Study: 31395751
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Binimetinib and Buparlisib)
Study: 31396142
Drug: Flavonoids- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoids- and Omega 3-Based Compound
Study: 31396983
Drug: PEX168 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168 200 μg (single abdominal subcutaneous injection)
Study: 31397291
Drug: Mobile Directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Directly Observed Therapy (Mobile DOT)
Study: 31397845
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (Tresiba)
Study: 31398081
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg IV) and Brentuximab Vedotin (1.8 mg/kg IV) every 3 weeks
Study: 31398082
Drug: AZD1775 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1775 (150 mg/d) in combination with gemcitabine (1,000 mg/m²) and radiation
Study: 31398204
Drug: School-based deworming
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based deworming intervention, specific dosage and duration not mentioned
Study: 31398245
Drug: Analysis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analysis of extra-ovarian cells (lymphocytes, buccal cells, urine cells) from the same patients.
Study: 31399043
Drug: HSV-1 based
Normalized name: HSV-1 G207
DrugBank: G207 (DB05827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSV-1 based oncolytic immunotherapy with GALV-GP-R
Study: 31399043
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with PD1/L1-targeted immune checkpoint blockade
Study: 31399255
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg daily)
Study: 31399936
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg QD for 8-21 days)
Study: 31399936
Drug: Ribociclib (monotherapy)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ribociclib (monotherapy)
Study: 31400383
Drug: Ephrin A2-targeted
Normalized name: PROCYANIDIN A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephrin A2-targeted liposomal prodrug at an equitoxic dose of 50 mg taxane/kg
Study: 31400383
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at a dose of 10 mg/kg
Study: 31400502
Drug: Tyrosine Kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine Kinase Inhibitors
Study: 31400961
Drug: Nivolumab in
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab in combination with idarubicin and cytarabine
Study: 31402238
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) - 3 doses
Study: 31402867
Drug: Loxapine; dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine; dosage and duration not specified
Study: 31404542
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg twice per day for 7 days)
Study: 31404569
Drug: Vaccine-offered condition
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-offered condition
Study: 31404802
Drug: Vortioxetine 10-20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10-20 mg open-label for 8 weeks
Study: 31405822
Drug: Rogaratinib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogaratinib at 800 mg twice daily
Study: 31407002
Drug: Drug-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-drug combinations (specific combinations include amoxicillin/clavulanate and diclofenac with steroid hormones)
Study: 31407002
Drug: Single drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drugs
Study: 31409407
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) sessions: 60 sessions of 90 minutes at 100% oxygen at 2 ATA with 5 min air breaks every 20 min, 5 days per week.
Study: 31410175
Drug: Irreversible electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irreversible electroporation ablation (IRE) therapy
Study: 31410294
Drug: PLAN 4
Normalized name: zilucoplan 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLAN 4 Success-Diabetes intervention (4-week health literacy training, disease knowledge education, 2 home visits, monthly phone counseling for 24 weeks)
Study: 31410992
Drug: Broccoli soup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli soup (300 mL portions, three times a week for four weeks)
Study: 31411949
Drug: De-intensified chemoradiotherapy
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-intensified chemoradiotherapy regimen of 60 Gy intensity-modulated radiotherapy with concurrent intravenous cisplatin 30 mg/m²
Study: 31412935
Drug: DS-8895a (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8895a (20 mg/kg) infused intravenously every 2 weeks
Study: 31413142
Drug: Veledimex (VDX)
Normalized name: Veledimex
DrugBank: Veledimex (DB12170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (VDX) 20 mg
Study: 31413142
Drug: Corticosteroids (dexamethasone)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corticosteroids (dexamethasone) >20 mg
Study: 31413142
Drug: Corticosteroids (dexamethasone)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corticosteroids (dexamethasone) ≤20 mg
Study: 31413142
Drug: Veledimex (VDX)
Normalized name: Veledimex
DrugBank: Veledimex (DB12170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (VDX) 20 mg cohort with corticosteroids >20 mg
Study: 31413142
Drug: Veledimex (VDX)
Normalized name: Veledimex
DrugBank: Veledimex (DB12170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex (VDX) 20 mg cohort with corticosteroids ≤20 mg
Study: 31413844
Drug: Diagnostic steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diagnostic steps and treatment decisions
Study: 31413865
Drug: Second-line TNF
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Second-line TNF inhibitors (TNFis)
Study: 31413865
Drug: Other biological
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other biological agents (tocilizumab (TCZ), rituximab, or abatacept)
Study: 31414396
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) adherence strategies informed by shared decision-making (SDM)
Study: 31414396
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) adherence strategies
Study: 31415416
Drug: Shujinjianyao pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shujinjianyao pill (SJJYP) for 4 weeks
Study: 31415566
Drug: Nifurtimox (NF)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox (NF) treatment for Chagas disease, median dose 9.75 mg/kg/day three times a day (TID) for 1 month
Study: 31416443
Drug: Patient Reported
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Reported Outcome Measures (PROMs) questionnaires administered before surgery, at 6 months, and at 12 months post-surgery
Study: 31417440
Drug: Computer-Assisted Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Assisted Cognitive-Behavioral Therapy
Study: 31417958
Drug: Pressurized Intra-Peritoneal
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) combined with systemic chemotherapy
Study: 31419065
Drug: AT1R-AA >40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1R-AA >40 U/mL
Study: 31419065
Drug: AT1R-AA <40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1R-AA <40 U/mL
Study: 31420042
Drug: SM04690, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SM04690, a small-molecule inhibitor of the Wnt signaling pathway
Study: 31420358
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg every 2 weeks
Study: 31420379
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose (ULD) chest CT using ASiR-V
Study: 31420379
Drug: Standard low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard low-dose (LD) CT
Study: 31420462
Drug: Edema-modifying therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edema-modifying therapies
Study: 31420849
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Erbium-YAG laser plus Platelet-rich plasma, 6 sessions of laser and 12 sessions of plasma over 6 months)
Study: 31421471
Drug: Fluorescently labeled
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorescently labeled anti-EGFR antibody (panitumumab-IRDye800CW)
Study: 31421933
Drug: Reduced-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reduced-dose apixaban 2.5mg BID
Study: 31421933
Drug: Standard-dose apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard-dose apixaban 5mg BID
Study: 31421933
Drug: Recommended reduced-dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recommended reduced-dose group
Study: 31421933
Drug: Non-recommended reduced-dose
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recommended reduced-dose group
Study: 31422129
Drug: Contrast ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast ultrasound with intravenous microbubble infusion for 10 min
Study: 31425781
Drug: Mepolizumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (40 mg for <40 kg or 100 mg for ≥40 kg) administered subcutaneously over 52 weeks
Study: 31427205
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily with dose titration every 14 days up to 10 mg twice daily)
Study: 31427205
Drug: Axitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (5 mg twice daily with dose titration)
Study: 31427321
Drug: GSK's split-virion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK's split-virion inactivated quadrivalent influenza vaccine
Study: 31428637
Drug: Balneophysiotherapeutic procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Balneophysiotherapeutic procedures (radon water therapy) for 21 days
Study: 31429027
Drug: Bavituximab 3
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab 3 mg/kg weekly and Sorafenib 400 mg twice daily
Study: 31429027
Drug: Bavituximab and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab and Sorafenib combination
Study: 31430318
Drug: Indirect adherence
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect adherence measures (Medication Possession Ratio, Pill Count, Self-Report)
Study: 31430405
Drug: Topical digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical digoxin and furosemide gel
Study: 31431117
Drug: Prescription rates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription rates of guideline-recommended medications
Study: 31431117
Drug: Utilization of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utilization of traditional Chinese medicine
Study: 31431998
Drug: TCZ-SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-SC 162 mg once weekly for 52 weeks (monotherapy)
Study: 31431998
Drug: TCZ-SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-SC 162 mg once weekly for 52 weeks (combination therapy with csDMARDs)
Study: 31431998
Drug: TCZ-SC (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ-SC (both monotherapy and combination therapy)
Study: 31432451
Drug: Under-dosing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under-dosing of rivaroxaban (less than 15 mg once daily)
Study: 31433768
Drug: Hiring staff
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hiring staff to perform discharge medication reconciliation
Study: 31433768
Drug: Training staff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training staff to take medication histories
Study: 31433920
Drug: Oral selinexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly
Study: 31434769
Drug: Antibiotic-related knowledge
Normalized name: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-related knowledge and attitudes in Chiang Rai
Study: 31434769
Drug: Antibiotic-related knowledge
Normalized name: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-related knowledge and attitudes in Salavan
Study: 31434769
Drug: Local expressions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local expressions for antibiotics in Chiang Rai
Study: 31434783
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of influenza-specific antibody titres against all vaccinated and circulated strains during the 2016/2017 season
Study: 31434793
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg per day orally plus another aromatase inhibitor
Study: 31434940
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy in TNBC (n=239)
Study: 31434940
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment in ER+/HER2-/LN- (n=1113)
Study: 31434940
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment in ER+/HER2-/LN+ (n=423)
Study: 31434940
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy and endocrine treatment in HER2+/ER+ (n=239)
Study: 31434940
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy and endocrine treatment in ER+/HER2-/LN+ (n=433)
Study: 31434940
Drug: Endocrine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine treatment in ER+/HER2-/LN- untreated (n=200)
Study: 31434940
Drug: HER2+/ER- with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2+/ER- with anti-HER2+ ACT treatment (n=110)
Study: 31434940
Drug: HER2+/ER+ with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2+/ER+ with anti-HER2+ ACT + endocrine treatment (n=239)
Study: 31438926
Drug: Discontinuation Prediction
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation Prediction Score (DiPS) using logistic regression and support vector machine methods